Share this Page:
Results from the phase 3 COSMIC-313 trial showed that adding cabozantinib to nivolumab plus ipilimumab for patients with previously untreated advanced kidney cancer with with moderate to high-risk disease significantly improved the time to when the treatment stopped working and the cancer started growing again (progression-free survival, PFS).
Serious or life-threatening side effects in the triple combination group and plus group, respectively.were reported by 79% of patients taking the triple combination and 56% on plus . 45% and 24% of patients stopped treatment because of
In summary, the triple combination of, and significantly improved the time to when the treatment stopped working and the started growing again compared to plus in patients with previously untreated advanced with moderate- to high-risk disease.
There were no newreported compared to previous trials using the medicines alone or in combination. The study continues to collect survival information.